1,841 results match your criteria Synovial Cell Sarcoma


Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas.

PLoS Comput Biol 2019 Feb 20;15(2):e1006826. Epub 2019 Feb 20.

Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.

Based on morphology it is often challenging to distinguish between the many different soft tissue sarcoma subtypes. Moreover, outcome of disease is highly variable even between patients with the same disease. Machine learning on transcriptome sequencing data could be a valuable new tool to understand differences between and within entities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pcbi.1006826DOI Listing
February 2019

Genotyping of circulating cell-free DNA enables non-invasive tumor detection in myxoid liposarcomas.

Int J Cancer 2019 Feb 18. Epub 2019 Feb 18.

Department of Plastic and Hand Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany.

Soft tissue sarcomas (STS) are rare tumors of mesenchymal origin. About 50% of patients with STS experience relapse and more than 30% will die within 10 years after diagnosis. In this study we investigated circulating free DNA (cfDNA) and tumor-specific genetic alterations therein (circulating tumor DNA, ctDNA) as diagnostic biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32216DOI Listing
February 2019

Proteomic signatures corresponding to the SS18/SSX fusion gene in synovial sarcoma.

Oncotarget 2018 Dec 25;9(101):37509-37519. Epub 2018 Dec 25.

Department of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan.

Synovial sarcoma (SS) is a malignant soft tissue lesion and most commonly arises in young adults. Chromosomal translocation t(X;18)(p11;q11) results in the formation of / by gene fusion of the SS18 gene on chromosome 18 to either , , or gene located on chromosome X, which is detected in more than 95% of SSs. Although multiple lines of evidence suggest that the fusion is the oncogene in this tumor, the protein expression profiles associated with / have yet to be elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331019PMC
December 2018

STAT6 Expression in Solitary Fibrous Tumor and Histologic Mimics: a Single Institution Experience.

Appl Immunohistochem Mol Morphol 2019 Jan 19. Epub 2019 Jan 19.

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN.

STAT6 stain has proved to be a good surrogate marker for the genetic alteration (NAB2-STAT6 gene fusion) in solitary fibrous tumor (SFT). This study aims to validate the use of STAT6 rabbit monoclonal antibody in differentiating SFT from its histologic mimics. Forty-five cases of SFT and 110 cases from 9 other spindle cell tumors were collected for STAT6 immunostaining. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000745DOI Listing
January 2019
2 Reads

New fusion sarcomas histopathology and clinical significance of selected entities.

Hum Pathol 2019 Jan 8. Epub 2019 Jan 8.

Laboratory of Pathology, National Cancer Institute, Bethesda, MD.

Many sarcomas contain gene fusions that can be pathogenetic mechanisms and diagnostic markers. In this article we review selected fusion sarcomas and techniques for their detection. CIC-DUX4 fusion sarcoma is a round-cell tumor now considered an entity separate from Ewing sarcoma with a more aggressive clinical course, occurrence in older age, and predilection to soft tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2018.12.006DOI Listing
January 2019
10 Reads

Analysis of mutations in primary and metastatic synovial sarcoma.

Oncotarget 2018 Dec 7;9(96):36878-36888. Epub 2018 Dec 7.

The Children's Guild Foundation Down Syndrome Research Program, Genetics and Genomics Program, Department of Cancer Genetics and Genomics, Roswell Park Cancer Institute, Buffalo, NY, USA.

Synovial sarcoma is the most common pediatric non-rhabdomyosarcoma soft tissue sarcoma and accounts for about 8-10% of all soft tissue sarcoma in childhood and adolescence. The presence of a chromosomal translocation-associated -fusion gene is causally linked to development of primary synovial sarcoma. Metastases occur in approximately 50-70% of synovial sarcoma cases with yet unknown mechanisms, which led to about 70-80% mortality rate in five years. Read More

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/26416
Publisher Site
http://dx.doi.org/10.18632/oncotarget.26416DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305143PMC
December 2018
4 Reads

Distal extremities soft tissue sarcomas: Are they so different from other limb localizations?

J Surg Oncol 2019 Mar 4;119(4):479-488. Epub 2019 Jan 4.

Faculté de Médecine de la Timone, Génétique Médicale et génomique fonctionnelle, UMR S910 Inserm, Université Aix-Marseille 2, Marseille, France.

Background And Objectives: Soft tissue sarcoma localization in distal extremities (DESTS) of the limbs (hand/fingers, and foot/toes) is unusual. The literature is scarce about their behavior and this study was designed to assess their epidemiological characteristics, outcomes, and prognosis compared to other limb localizations (OLSTS).

Methods: From 1980 to 2010, adult DESTS and OLSTS in 22 centers were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.25359DOI Listing
March 2019
2 Reads

Frequent TLE1 Expression in Cutaneous Neoplasms.

Am J Dermatopathol 2019 Jan;41(1):1-6

Dermatopathologist, Department of Pathology, University of Massachusetts Medical School, UMass Memorial Medical Center, Worcester, MA.

TLE1 immunohistochemistry is widely used as a biomarker for synovial sarcoma. Recently, we identified TLE1 expression in a subset of melanomas and noted staining in sebaceous glands and follicular epithelium. TLE1 immunohistochemistry has not been well studied in cutaneous tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001186DOI Listing
January 2019
2 Reads

An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing.

Genes Chromosomes Cancer 2019 02 24;58(2):88-99. Epub 2018 Dec 24.

Department of Pathology, The Royal National Orthopaedic Hospital, Stanmore, Middlesex, United Kingdom.

The last decade has seen the majority of primary bone tumor subtypes become defined by molecular genetic alteration. Examples include giant cell tumour of bone (H3F3A p.G34W), chondroblastoma (H3F3B p. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/gcc.22699
Publisher Site
http://dx.doi.org/10.1002/gcc.22699DOI Listing
February 2019
6 Reads

A recurrent novel fusion identifies a new subtype of high-grade spindle cell sarcoma.

Cold Spring Harb Mol Case Stud 2018 Dec 17;4(6). Epub 2018 Dec 17.

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

-rearranged tumors are defined by the presence of a gene fusion between and various gene partners and typically follow a clinically aggressive disease course with poor outcomes despite conventional multimodality therapy. -rearranged tumors display histologic features of a poorly differentiated carcinoma with areas of focal squamous differentiation and typically express the fusion gene defining a distinct clinicopathologic entity-NUT carcinoma (NC). NCs with mesenchymal differentiation have rarely been described in the literature. Read More

View Article

Download full-text PDF

Source
http://molecularcasestudies.cshlp.org/lookup/doi/10.1101/mcs
Publisher Site
http://dx.doi.org/10.1101/mcs.a003194DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318763PMC
December 2018
17 Reads

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy.

Oncoimmunology 2018 11;7(12):e1507600. Epub 2018 Sep 11.

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Synovial sarcoma expresses multiple cancer testis antigens that could potentially be targeted by T-cell receptor (TCR) gene therapy. In this study we investigated whether PRAME-TCR-gene therapy could be an effective treatment for synovial sarcoma by investigating the potential of PRAME-specific T-cells to recognize sarcoma cells and by evaluating the expression patterns of and HLA class I (HLA-I) in synovial sarcoma tumor samples. All expressing sarcoma cell lines, including 2 primary synovial sarcoma cell cultures (passage < 3), were efficiently recognized by PRAME-specific T-cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2018.1507600DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279314PMC
September 2018
1 Read
6.283 Impact Factor

Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in Japan.

Clin Ther 2019 Jan 7;41(1):174-184.e3. Epub 2018 Dec 7.

Department of Translational Research Promotion Incubation Center for Advanced Medical Science, Kyushu University, Fukuoka, Japan.

Purpose: In Japan, gene therapy and cellular therapy are categorized as regenerative medicine products based on the Pharmaceuticals and Medical Devices Law that was implemented in 2014. In this new law, regenerative medicine products were newly defined, and a conditional and term-limited approval system for regenerative medicine products was instituted. In addition, the Ministry of Health, Labour and Welfare instituted the SAKIGAKE (meaning pioneer or forerunner in Japanese) designation system in 2015. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01492918183055
Publisher Site
http://dx.doi.org/10.1016/j.clinthera.2018.11.003DOI Listing
January 2019
9 Reads

Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma.

J Orthop Res 2018 Nov 28. Epub 2018 Nov 28.

Sarcoma Biology Laboratory, Department of Orthopaedic Surgery, David Geffen School of Medicine at University of California Los Angeles, 615 Charles E. Young Dr. S., Los Angeles, California, 90095.

Synovial sarcomas hold a low genomic complexity, making it distinct from other types of soft-tissue sarcomas. Many studies focused on targeting the SS18-SSX fusion protein, which presents in over 90% of human synovial sarcomas. This protein acts as an oncogenic promoter in the tumorigenesis of synovial sarcomas, making it an ideal therapeutic target. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jor.24189DOI Listing
November 2018
10 Reads

Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms.

Head Neck Pathol 2018 Nov 22. Epub 2018 Nov 22.

Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.

Head and neck pathology present a unique set of challenges including the morphological diversity of the neoplasms and presentation of metastases of unknown primary origin. The detection of human papillomavirus and Epstein-Barr virus associated with squamous cell carcinoma and newer entities like HPV-related carcinoma with adenoid cystic like features have critical prognostic and management implications. In salivary gland neoplasms, differential diagnoses can be broad and include non-neoplastic conditions as well as benign and malignant neoplasms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12105-018-0988-1DOI Listing
November 2018
10 Reads

Pazopanib-induced changes in protein expression signatures of extracellular vesicles in synovial sarcoma.

Biochem Biophys Res Commun 2018 Nov 27;506(3):723-730. Epub 2018 Oct 27.

Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Department of Innovative Seeds Evaluation, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Electronic address:

Secreted proteins enclosed in extracellular vesicles can act as intercellular messengers. The objective of this study was to elucidate the role of proteins secreted from synovial sarcoma cells in the regulatory network underlying pazopanib response. We performed a comprehensive analysis of expression of proteins secreted from four synovial sarcoma cell lines (SYO-1, HS-SYII, 1273/99, and YaFuSS) using mass spectroscopy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2018.10.012DOI Listing
November 2018
5 Reads

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.

Elife 2018 11 15;7. Epub 2018 Nov 15.

Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School, Boston, United States.

Synovial sarcoma tumours contain a characteristic fusion protein, SS18-SSX, which drives disease development. Targeting oncogenic fusion proteins presents an attractive therapeutic opportunity. However, SS18-SSX has proven intractable for therapeutic intervention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7554/eLife.41305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277197PMC
November 2018
16 Reads
8.520 Impact Factor

miR‑494.3p expression in synovial sarcoma: Role of CXCR4 as a potential target gene.

Int J Oncol 2019 Jan 6;54(1):361-369. Epub 2018 Nov 6.

Laboratory of Experimental Oncology, IRCCS, Rizzoli Orthopedic Institute, I‑40136 Bologna, Italy.

Synovial sarcoma (SS) is a rare tumour, with dismal survival when metastasis occurs. SS contains a characteristic translocation (X;18)(p11;q11) and the fusion genes appear to be mutually exclusive and concordant in primary and metastatic tumours. Novel prognostic and predictive factors are required. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ijo.2018.4627
Publisher Site
http://dx.doi.org/10.3892/ijo.2018.4627DOI Listing
January 2019
12 Reads

Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines.

Oncotarget 2018 Oct 12;9(80):35141-35161. Epub 2018 Oct 12.

Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.

Treatment of patients with advanced sarcoma remains challenging due to lack of effective medicine, with the development of novel drugs being of keen interest. A pan-PI3K inhibitor, ZSTK474, has been evaluated in clinical trials against a range of advanced solid tumors, with clinical benefit shown in sarcoma patients. In the present study, we developed a panel of 14 human sarcoma cell lines and investigated the antitumor effect of 24 anticancer agents including ZSTK474, other PI3K inhibitors, and those clinically used for sarcoma treatment. Read More

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/26216
Publisher Site
http://dx.doi.org/10.18632/oncotarget.26216DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205545PMC
October 2018
15 Reads

The small molecule NSM00191 specifically represses the TNF-α/NF-кB axis in foot and ankle rheumatoid arthritis.

Int J Biol Sci 2018 3;14(12):1732-1744. Epub 2018 Oct 3.

Department of Orthopaedics, HongHui Hospital, Xi'an Jiaotong University, Xi'an 710054, Shaanxi, China.

The activation of TNF-α/NF-кB signaling is involved in the regulation of a wide range of biological processes, such as cell proliferation, differentiation and apoptosis, eventually causing a number of diseases, such as cancer and inflammation. Here, we found that TNF-α/NF-кB signaling was activated in a large number of blood samples taken from foot and ankle rheumatoid arthritis (RA) patients. By applying a microarray assay to the human synovial sarcoma cell line SW982 and the human fibroblast-like synoviocyte cell line HFLS-RA, as well as in their corresponding p65 knockdown and -overexpressing cells, we identified and verified the activation of many p65 targets, including cytokines (e. Read More

View Article

Download full-text PDF

Source
http://www.ijbs.com/v14p1732.htm
Publisher Site
http://dx.doi.org/10.7150/ijbs.24232DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216029PMC
October 2018
6 Reads

TLE1 Positive Clear Cell Sarcoma of the Kidney: A Case Report and Review of the Literature.

Authors:
Rana Naous

Case Rep Pathol 2018 16;2018:3462096. Epub 2018 Oct 16.

Department of Pathology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA.

Clear cell sarcoma of the kidney (CCSK) is an uncommon malignant tumor of uncertain histogenesis that occurs most commonly in childhood. Histologically, CCSK can mimic myxoid variant of synovial sarcoma (SS); however, the double positivity for CD99 and TLE1 in SS helps in excluding CCSK. Herein, we report a rare case of CCSK arising in the left kidney of a 3-year-old girl. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/cripa/2018/3462096/
Publisher Site
http://dx.doi.org/10.1155/2018/3462096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206519PMC
October 2018
9 Reads

Synovial sarcoma of the brachial plexus - a rare tumor in a rare area: a case report.

J Med Case Rep 2018 Nov 9;12(1):334. Epub 2018 Nov 9.

Dr. Paul Brand Centre for Hand and Peripheral Nerve Surgery, Vellore, India.

Background: Synovial cell sarcomas are usually seen in a juxta-articular location. However, they occur rarely in the head and neck region.

Case Presentation: We report a rare case of brachial plexus synovial sarcoma in a 24-year old South Asian man treated successfully with surgical excision followed by radiotherapy. Read More

View Article

Download full-text PDF

Source
https://jmedicalcasereports.biomedcentral.com/articles/10.11
Publisher Site
http://dx.doi.org/10.1186/s13256-018-1860-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225558PMC
November 2018
8 Reads

A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation.

Nat Cell Biol 2018 Dec 5;20(12):1410-1420. Epub 2018 Nov 5.

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

Mammalian SWI/SNF chromatin remodelling complexes exist in three distinct, final-form assemblies: canonical BAF (cBAF), PBAF and a newly characterized non-canonical complex (ncBAF). However, their complex-specific targeting on chromatin, functions and roles in disease remain largely undefined. Here, we comprehensively mapped complex assemblies on chromatin and found that ncBAF complexes uniquely localize to CTCF sites and promoters. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41556-018-0221-1
Publisher Site
http://dx.doi.org/10.1038/s41556-018-0221-1DOI Listing
December 2018
35 Reads

NKX2.2 immunohistochemistry in the distinction of Ewing sarcoma from cytomorphologic mimics: Diagnostic utility and pitfalls.

Cancer Cytopathol 2018 Nov 30;126(11):942-949. Epub 2018 Oct 30.

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Background: Ewing sarcoma (ES) is a round cell sarcoma that can be challenging to diagnose on cytologic material given its significant overlap with numerous mesenchymal, epithelial, and lymphoid cytomorphologic mimics. The objective of this study was to assess the utility of a novel marker, NKX2.2, in the diagnosis of ES in cytologic material and its ability to distinguish ES from its mimics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncy.22056DOI Listing
November 2018
5 Reads

[Synovial sarcoma of the right forearm].

Pan Afr Med J 2018 13;30:124. Epub 2018 Jun 13.

Service de Radiologie, Hôpital Militaire d'Instruction Mohammed V, Rabat, Maroc.

We report the case of a 60-year old female patient, followed up for hypertensive heart disease for 04 years, presenting to the Dermatological Department with a mass in the right forearm which had evolved and gradually increased in size over the previous year. Clinical examination showed soft rounded, voluminous painless, tumor-like crusted ulcerative lesion measuring 8 cm in large-diameter, fixed with respect to both planes, at the level of the mid-parts of the posterolateral area of the right forearm (A). Standard X-ray showed homogeneous opaque mass with sparing of the opposite cortex (B). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11604/pamj.2018.30.124.15900DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201604PMC
November 2018
4 Reads

Calcifying Nested Stromal-Epithelial Tumor of the Liver: An Update and Literature Review.

Arch Pathol Lab Med 2019 Feb 24;143(2):264-268. Epub 2018 Oct 24.

From the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.

Calcifying nested stromal-epithelial tumor is a rare entity that has gone by a variety of names in the literature: ossifying malignant mixed epithelial and stromal tumor, ossifying stromal-epithelial tumor, and desmoplastic nested spindle cell tumor of the liver. To our knowledge, approximately 38 cases have been reported in the literature. The histogenesis is still largely unknown but histopathologically is characterized by nests of spindle and epithelioid cells in an organoid arrangement surrounded by a prominent dense myofibroblastic stroma with occasional psammomatous calcification and focal heterotopic ossification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2017-0346-RSDOI Listing
February 2019
4 Reads

Clinical and radiographic presentation of pelvic sarcoma in children.

SICOT J 2018 19;4:44. Epub 2018 Oct 19.

Department of Orthopaedics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

Introduction: Pelvic sarcomas may present with vague symptoms. The aim of this study was to examine the characteristics and clinical presentations of different types of pelvic sarcoma in children.

Methods: This is a retrospective cohort study of patients up to 21 years of age with the diagnosis of pelvic sarcoma between January 2000 and June 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1051/sicotj/2018040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195345PMC
October 2018
8 Reads

Release of circulating tumor cells and cell-free nucleic acids is an infrequent event in synovial sarcoma: liquid biopsy analysis of 15 patients diagnosed with synovial sarcoma.

Diagn Pathol 2018 Oct 17;13(1):81. Epub 2018 Oct 17.

1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, Budapest, H-1085, Hungary.

Background: Synovial sarcoma is a rare soft tissue tumor which contains the unique SS18-SSX1, SS18-SSX2 - or, rarely, SS18-SSX4 - fusion transcripts. It is well known that some soft tissue tumors, like Ewing sarcomas and myxoid liposarcomas, can spread via the blood with free circulating tumor cells (CTC); this can be detected by several sensitive molecular biology methods. Here we report a study of fifteen synovial sarcoma patients with varied clinical backgrounds. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13000-018-0756-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191904PMC
October 2018
1 Read

Rearrangement and CD99 Expression as Diagnostic Biomarkers for Ewing/PNET Sarcomas in a Moroccan Population.

Dis Markers 2018 18;2018:7971019. Epub 2018 Sep 18.

Pathological Anatomy and Molecular Pathology Department, Hassan II University Hospital of Fez, Morocco.

Ewing sarcoma/primitive neuroectodermal tumor (Ewing/PNET sarcomas or EPS) are a group of round cell tumors. Malignant round cell tumors form a large and diverse group that includes rhabdomyosarcoma, synovial sarcoma, non-Hodgkin's lymphoma, neuroblastoma, hepatoblastoma, Wilm's tumor, desmoplastic small round cell tumor, and other morphologically similar entities. Differential diagnosis of Ewing sarcoma/primitive neuroectodermal tumor (Ewing/PNET sarcomas or EPS) is difficult. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/dm/2018/7971019/
Publisher Site
http://dx.doi.org/10.1155/2018/7971019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167566PMC
January 2019
6 Reads

Expression of TLE1 in Malignant Melanoma With Spindle Cell Morphology: A Potential Diagnostic Pitfall.

Int J Surg Pathol 2018 Oct 10:1066896918805137. Epub 2018 Oct 10.

1 University of Massachusetts Medical School, UMass Memorial Medical Center, Worcester, MA, USA.

Objectives: Transducer-like enhancer of split 1 (TLE1) immunohistochemistry is widely used as a biomarker of synovial sarcoma. Spindle cell or desmoplastic melanoma can morphologically mimic synovial sarcoma. The aim of this study was to investigate the expression of TLE1 in melanomas with a spindle cell morphology. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1066896918805137
Publisher Site
http://dx.doi.org/10.1177/1066896918805137DOI Listing
October 2018
2 Reads

Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model.

Anticancer Res 2018 Oct;38(10):5639-5644

AntiCancer, Inc., San Diego, CA, U.S.A.

Background/aim: Synovial sarcoma (SS) is a recalcitrant neoplasm with low chemosensitivity. We recently reported that recombinant methioninase (rMETase) inhibited SS growth in a patient-derived orthotopic xenograft (PDOX) mouse model and was more effective when administered in combination with the first-line drug doxorubicin (DOX). Caffeine enhances the efficacy of anticancer drugs by overcoming drug-induced cell-cycle arrest and increasing subsequent apoptosis. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.12
Publisher Site
http://dx.doi.org/10.21873/anticanres.12899DOI Listing
October 2018
4 Reads

Left neck undifferentiated sarcoma with synchronous left kidney renal cell carcinoma.

Radiol Case Rep 2018 Oct 19;13(5):1087-1090. Epub 2018 May 19.

University of Texas Medical Branch 301 University Boulevard, Galveston, Texas, 77555, USA.

Parapharyngeal space sarcomas are rare malignancies and most in the reported literature are synovial sarcomas. Here we present the case of a 27-year-old female with a painless, left-sided neck mass who underwent computed tomography and magnetic resonance imaging evaluation which demonstrated a benign appearing mass that upon resection unexpectedly proved to be a high-grade undifferentiated sarcoma with rhabdoid features. Staging computed tomography revealed a synchronous renal cell carcinoma with clear cell and papillary features. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radcr.2018.04.027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137406PMC
October 2018
3 Reads

SOX11: a potentially useful marker in surgical pathology: a systematic analysis of SOX11 expression in epithelial and non-epithelial tumours.

Histopathology 2019 Feb 2;74(3):391-405. Epub 2018 Dec 2.

Institute of Pathology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.

Aims: SOX11 is known as an essential transcription factor for regulating neurogenesis. Recently, SOX11 has been suggested to be a diagnostic marker and oncogene because of its significant expression in mantle cell lymphoma (MCL). However, SOX11 expression in other tumour types has not yet been extensively studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13757DOI Listing
February 2019
14 Reads

In silico and in vitro screening of small molecule Inhibitors against SYT-SSX1 fusion protein in synovial sarcoma.

Comput Biol Chem 2018 Dec 6;77:36-43. Epub 2018 Sep 6.

Dept of Molecular Oncology, Dr. S. Krishnamurthi Campus, Cancer Institute (WIA), Guindy, Chennai, 600036, India. Electronic address:

Synovial sarcoma (SS) is characterized by a tumour specific chromosomal translocation t(X;18) (p11;q11) which results in the formation of SYT-SSX1 fusion protein. This fusion protein represents a clear therapeutic target and molecules specifically targeting SYT-SSX1 fusion protein are currently not available. In this study, SYT-SSX1 fusion protein sequence was retrieved from Uniprot and 3D structure was generated using I-TASSER modeling program. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14769271183029
Publisher Site
http://dx.doi.org/10.1016/j.compbiolchem.2018.09.006DOI Listing
December 2018
7 Reads

PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin.

PET Clin 2018 Oct;13(4):609-621

Keck School of Medicine, University of Southern California (USC), 1520 San Pablo Street, Suite L1600, Los Angeles, CA 90033.

Soft tissue sarcomas (STSs) account for less than 1% of adult solid tumors and about 7% of pediatric malignancies, causing 2% of cancer-related deaths. With the advent of PET-computed tomography (CT), the value of (18) fluorine-2-fluoro-2-deoxy-d-glucose (FDG) PET imaging to improve the management of STSs has been explored. FDG PET imaging has been found useful in restaging and treatment response assessment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpet.2018.05.011DOI Listing
October 2018
4 Reads

Genetic and molecular reappraisal of spindle cell adamantinoma of bone reveals a small subset of misclassified intraosseous synovial sarcoma.

Mod Pathol 2019 Feb 11;32(2):231-241. Epub 2018 Sep 11.

Department of Pathology, Mayo Clinic, Rochester, MN, USA.

Adamantinoma represents a distinct group of bone tumors showing both mesenchymal and epithelial differentiation most commonly involving the tibial diaphysis. Most adamantinomas contain a fibro-osseous component and an epithelial component consisting of squamous or basaloid cells. Adamantinomas are considered malignant neoplasms requiring en bloc excision that frequently recur locally and can rarely metastasize. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41379-018-0115-6
Publisher Site
http://dx.doi.org/10.1038/s41379-018-0115-6DOI Listing
February 2019
6 Reads

Malignant Tenosynovial Giant Cell Tumor: The True "Synovial Sarcoma?" A Clinicopathologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases, Supporting Origin from Synoviocytes.

Mod Pathol 2019 Feb 11;32(2):242-251. Epub 2018 Sep 11.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

We present our experience with ten well-characterized malignant tenosynovial giant cell tumors, including detailed immunohistochemical analysis of all cases and molecular cytogenetic study for CSF1 rearrangement in a subset. Cases occurred in 7 M and 3 F (mean age: 52 years; range: 26-72 years), and involved the ankle/foot (n = 1), finger/toe (n = 3), wrist (n = 1), pelvic region (n = 3), leg (n = 1), and thigh (n = 1). There were eight primary and two secondary malignant tenosynovial giant cell tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-018-0129-0DOI Listing
February 2019
9 Reads

Periostin expression in neoplastic and non-neoplastic diseases of bone and joint.

Clin Sarcoma Res 2018 5;8:18. Epub 2018 Sep 5.

1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal and Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, OX3 7HE UK.

Background: Periostin is a matricellular protein that is expressed in bone and joint tissues. To determine the expression of periostin in primary bone tumours and to assess whether it plays a role in tumour progression, we carried out immunohistochemistry and ELISA for periostin in a range of neoplastic and non-neoplastic bone and joint lesions.

Methods: 140 formalin-fixed paraffin-embedded sections of bone tumours and tumour-like lesions were stained by an indirect immunoperoxidase technique with a polyclonal anti-periostin antibody. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13569-018-0105-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123976PMC
September 2018
7 Reads

Next frontiers in systemic therapy for soft tissue sarcoma.

Chin Clin Oncol 2018 Aug;7(4):43

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan; National Taiwan University Cancer Center, Taipei.

Soft tissue sarcoma (STS) is a heterogeneous disease with more than 50 subtypes. Once the disease reached locally advanced or metastatic status, the standard treatment remains to be chemotherapy. Current understanding of the underlying molecular and genomic mechanisms of different histology subtypes have led to encouraging development of new drugs in treating STS. Read More

View Article

Download full-text PDF

Source
http://cco.amegroups.com/article/view/20947/20601
Publisher Site
http://dx.doi.org/10.21037/cco.2018.08.04DOI Listing
August 2018
13 Reads

The role of immunohistochemistry in the diagnosis and management of synovial sarcoma.

Rom J Morphol Embryol 2018 ;59(2):569-572

Department of Anatomy and Embryology, Department of Medical Radiology and Imagistics, "Victor Babeş" University of Medicine and Pharmacy, Timişoara, Romania;

Synovial sarcoma (SS) is a malignant soft tissue tumor representing 5-10% of all soft tissue sarcomas. Most synovial sarcomas are found at the extremities, especially in the lower limbs. A 28-year-old female presented at the Department of Plastic and Reconstructive Surgery, "Dr. Read More

View Article

Download full-text PDF

Source
December 2018
14 Reads

Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma.

Mol Cancer Ther 2018 Nov 30;17(11):2329-2340. Epub 2018 Aug 30.

Department of Medicine, Columbia University Medical Center, New York, New York.

Sarcomas are rare cancers that make up about 1% of all cancers in adults; however, they occur more commonly among children and young adolescents. Sarcomas are genetically complex and are often difficult to treat given the lack of clinical efficacy of any of the currently available therapies. Receptor tyrosine kinases (RTK) such as c-Kit, c-Met, PDGFR, IGF-1R, as well as FGFR have all been reported to be involved in driving tumor development and progression in adult and pediatric soft-tissue sarcoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-18-0319DOI Listing
November 2018
4 Reads

Prognostic impact of the tumor immune microenvironment in synovial sarcoma.

Cancer Sci 2018 Oct 16;109(10):3043-3054. Epub 2018 Sep 16.

Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.

The association between the immune status within the tumor microenvironment and prognosis in synovial sarcoma is not well understood. We aimed to investigate the tumor immune microenvironment and analyze its prognostic impact for patients with synovial sarcoma. A total of 36 primary patients who were treated in our institution were retrospectively evaluated. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13769
Publisher Site
http://dx.doi.org/10.1111/cas.13769DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172059PMC
October 2018
9 Reads

The oncomir face of microRNA-206: A permanent miR-206 transfection study.

Exp Biol Med (Maywood) 2018 Aug 15;243(12):1014-1023. Epub 2018 Aug 15.

1 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest H-1085, Hungary.

MiR-206 is a remarkable miRNA because it functions as a suppressor miRNA in rhabdomyosarcoma while at the same time, as previously showed, it can act as an oncomiRNA in SMARCB1 immunonegative soft tissue sarcomas. The aim of this study was to investigate the effect of miR-206 on its several target genes in various human tumorous and normal cell lines. In the current work, we created miR-206-overexpressing cell lines (HT-1080, Caco2, iASC, and SS-iASC) using permanent transfection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1535370218795406DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180408PMC
August 2018
4 Reads

Engineered T Cells in Synovial Sarcoma: Persistence Pays Off!

Cancer Discov 2018 Aug;8(8):914-917

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Synovial sarcoma (SS) is an aggressive malignancy that typically affects adolescents and young adults and is associated with poor prognosis. Although SS has failed to respond to immune checkpoint blockade, other strategies designed to generate an immune response, including adoptive cell therapies targeting the cancer testis antigen NY-ESO-1, have shown encouraging results. In this issue, D'Angelo and colleagues confirm the safety and feasibility of adoptive T-cell therapy with autologous T cells engineered to express NY-ESO-1, an affinity-enhanced T-cell receptor recognizing an HLA-A2-restricted NY-ESO-1-derived peptide, and demonstrate encouraging antitumor responses in 50% of treated patients, particularly in the setting of persistence of polyfunctional NY-ESO-1-expressing T cells in circulation for at least 6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0618DOI Listing
August 2018
1 Read

Beclin1 overexpression suppresses tumor cell proliferation and survival via an autophagy‑dependent pathway in human synovial sarcoma cells.

Oncol Rep 2018 Oct 25;40(4):1927-1936. Epub 2018 Jul 25.

Department of Joint Surgery, Xi'an Hong Hui Hospital, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710054, P.R. China.

Beclin1 is an important autophagy‑related prot-ein, which is involved in both autophagy and apoptosis. In recent years, the antitumor effect of Beclin1 has received increased attention. In the present study, we established a stable Beclin1‑overexpressing cell line with SW982 human synovial sarcoma cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2018.6599DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111547PMC
October 2018
1 Read